Dogma Therapeutics has discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species.  Guided by dozens of high-resolution x-ray structures of their molecules bound to PCSK9, they have utilized structure-based design to achieve picomolar affinity.